The COVID-19 pandemic has challenged the healthcare community and care seekers to reimagine how we interact and how we deliver and consume care.
While regulatory checks and balances are needed to minimize waste and contain costs in the healthcare system, right now it is more important to minimize barriers to care as these can lead to unintended consequences. CMS and payers agree. As such, the Centers for Medicare & Medicaid Services (CMS) has adjusted some rules so that HCPs can focus on those who need care, and patients can access timely care with relative ease.
Survey responses indicate that payers are being nimble and flexible, allowing HCPs to do their best work and provide support to patients when they are most vulnerable.
While payers are shifting focus to COVID-19, they remain committed to sound formulary and coverage strategies that promote the use of safe and cost-effective medications. Payers are not able to engage with the pharmaceutical industry in person, but the interest in collaboration remains strong. Here are some insights you may want to consider when engaging payers:
Every effort is being made to continue pharmacy & therapeutic (P&T) meetings on schedule but there may be some payers who postpone/cancel P&T meetings.
Please contact your account leads or email@example.com if you have any questions or would like to discuss any of the above.